Reid Thomas, MD
Internal Medicine · Searcy, ARNPI 1427013945
Payments from drug & device makers
Across 324 payments — averaging $15.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$988
- Novo Nordisk$935
- GSK$664
- Pfizer$515
- AstraZeneca$428
- Sanofi-aventis U.S. LLC$375
- plus $1K from 20 others
What the payments were for
- Food & beverage$5,107100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 59 | $988 |
| Novo Nordisk | 61 | $935 |
| GSK | 47 | $664 |
| Pfizer | 32 | $515 |
| AstraZeneca | 24 | $428 |
| Sanofi-aventis U.S. LLC | 28 | $375 |
| AbbVie(2 entities) | 15 | $192 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $137 |
| Mylan Specialty L.p. | 7 | $125 |
| Nestle Healthcare Nutrition Inc. | 5 | $95 |
| Medtronic | 4 | $86 |
| Lilly USA, LLC | 6 | $80 |
| Abbott | 4 | $70 |
| Sequel Med Tech, LLC | 2 | $66 |
| E.r. Squibb & Sons, L.L.C. | 4 | $49 |
| Johnson & Johnson | 3 | $49 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $41 |
| Teva Pharmaceuticals USA, Inc. | 2 | $40 |
| Novartis | 2 | $40 |
| Boehringer Ingelheim | 1 | $24 |
| Phathom Pharmaceuticals, Inc. | 3 | $22 |
| Corcept Therapeutics | 1 | $22 |
| Alkermes, Inc. | 1 | $21 |
| Dexcom, Inc. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Eisai Inc. | 1 | $12 |
How this compares
$5,107 in reported general payments places this provider in the 90th percentile of 614 internal medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 214 | $219,746 |
| EliquisApixaban | 162 | $111,659 |
| TrulicityDulaglutide | 73 | $82,956 |
| JardianceEmpagliflozin | 74 | $64,742 |
| Repatha SureclickEvolocumab | 59 | $46,708 |
| Bydureon BciseExenatide Microspheres | 44 | $38,576 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 40 | $36,037 |
| MounjaroTirzepatide | 28 | $30,993 |
| XareltoRivaroxaban | 37 | $30,930 |
| RybelsusSemaglutide | 25 | $30,368 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 31 | $25,303 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $21,275 |
| JanuviaSitagliptin Phosphate | 24 | $18,570 |
| FarxigaDapagliflozin Propanediol | 30 | $18,100 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $17,703 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $935 | $250,114239 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $80 | $113,949101 claims |
| PfizerEliquis | $515 | $111,659162 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $24 | $73,49892 claims |
| Johnson & JohnsonXarelto | $49 | $30,93037 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $375 | $30,17361 claims |
| GSKBreo Ellipta, Incruse Ellipta | $664 | $25,65447 claims |
| AstraZenecaFarxiga, Symbicort | $428 | $23,08851 claims |
| AbbVieLinzess, Synthroid | $192 | $16,920127 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 614 internal medicine providers in Arkansas.
Other internal medicine in Searcy
- David JohnsonSearcy$630K
- John HendersonSearcy$102K
- Priyantha WijewardaneLittle Rock$43.6M
- Joseph RoseLittle Rock$1.1M
- Kathleen GannonRogers$450K
- Alexander KaczenskiLittle Rock$305K
- David PyleJonesboro$93K
- Manisha SinghLittle Rock$71K
- Govinda LohaniN Little Rock$55K
- Srikanth VallurupalliLittle Rock$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.